Details of the Drug

General Information of Drug (ID: DMH5MVE)

Drug Name

Sodium stibogluconate

Synonyms

Lenocta; Sodium stibogluconate (cancer); VQD-001; Sodium stibogluconate (cancer), Greenwich; Sodium stibogluconate (cancer), VioQuest

Indication

Disease Entry	ICD 11	Status	REF
Advanced cancer	2A00-2F9Z	Approved	[1]
Leishmaniasis	1F54	Approved	[2]
Solid tumour/cancer	2A00-2F9Z	Phase 2	[3]
------------------------------------------------------------------------------------

Structure

3D MOL

2D MOL

Cross-matching ID

PubChem CID: 16683012
DrugBank ID: DB05630
TTD ID: D09BBW

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Leishmania DNA topoisomerase I (Leishm TOP1)	TTNJKC3	Q9NJG8_LEIDO	Modulator	[3]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
B-cell lymphoma 6 protein (BCL6)	OTQAWWO1	BCL6_HUMAN	Gene/Protein Processing	[4]
C-C motif chemokine 2 (CCL2)	OTAD2HEL	CCL2_HUMAN	Gene/Protein Processing	[5]
Erythropoietin (EPO)	OTZ90CN4	EPO_HUMAN	Gene/Protein Processing	[6]
Integrin alpha-M (ITGAM)	OTAG6HWU	ITAM_HUMAN	Gene/Protein Processing	[7]
Interferon gamma (IFNG)	OTXG9JM7	IFNG_HUMAN	Gene/Protein Processing	[5]
Interferon gamma receptor 1 (IFNGR1)	OTCTQBWW	INGR1_HUMAN	Gene/Protein Processing	[8]
Interleukin-1 beta (IL1B)	OT0DWXXB	IL1B_HUMAN	Gene/Protein Processing	[5]
Interleukin-10 (IL10)	OTIRFRXC	IL10_HUMAN	Gene/Protein Processing	[5]
Interleukin-4 (IL4)	OTOXBWAU	IL4_HUMAN	Gene/Protein Processing	[5]
Tumor necrosis factor (TNF)	OT4IE164	TNFA_HUMAN	Gene/Protein Processing	[5]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	Perspectives of antimony compounds in oncology. Acta Pharmacol Sin. 2008 Aug;29(8):881-90.
2	Leishmaniasis in Norway. Tidsskr Nor Laegeforen. 2021 Feb 22;141(3).
3	Inhibition of Leishmania donovani promastigote DNA topoisomerase I and human monocyte DNA topoisomerases I and II by antimonial drugs and classical antitopoisomerase agents. J Parasitol. 2004 Oct;90(5):1155-62.
4	SHP-1 is directly activated by the aryl hydrocarbon receptor and regulates BCL-6 in the presence of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Toxicol Appl Pharmacol. 2016 Nov 1;310:41-50. doi: 10.1016/j.taap.2016.08.014. Epub 2016 Aug 18.
5	Evaluation of localized and systemic immune responses in cutaneous leishmaniasis caused by Leishmania tropica: interleukin-8, monocyte chemotactic protein-1 and nitric oxide are major regulatory factors. Immunology. 2010 Jun;130(2):193-201. doi: 10.1111/j.1365-2567.2009.03223.x. Epub 2010 Jan 22.
6	Serum erythropoietin concentration in anaemia of visceral leishmaniasis (kala-azar) before and during antimonial therapy. Br J Haematol. 1998 Mar;100(4):720-4. doi: 10.1046/j.1365-2141.1998.00624.x.
7	Effects of sodium stibogluconate on differentiation and proliferation of human myeloid leukemia cell lines in vitro. Leukemia. 2002 Nov;16(11):2285-91. doi: 10.1038/sj.leu.2402692.
8	Antileishmanial drugs cause up-regulation of interferon-gamma receptor 1, not only in the monocytes of visceral leishmaniasis cases but also in cultured THP1 cells. Ann Trop Med Parasitol. 2003 Apr;97(3):245-57. doi: 10.1179/000349803235001714.